Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography

Journal of Psychiatry and Neuroscience

Volumn 36, Issue 3, 2011, Pages 187-194

  Krogias, Christos ^a   Strassburger, Katrin ^a   Eyding, Jens ^a   Gold, Ralf ^a   Norra, Christine ^b   Juckel, Georg ^b   Saft, Carsten ^a   Ninphius, Dietmar ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BACLOFEN; BIPERIDEN; CARBAMAZEPINE; CHLORPROTHIXENE; CITALOPRAM; DOXEPIN; FLUOXETINE; HALOPERIDOL; LEVOTHYROXINE; LORAZEPAM; MAPROTILINE; MELPERONE; MEMANTINE; MIRTAZAPINE; OPIPRAMOL; PIRACETAM; PIRENZEPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TETRABENAZINE; TIAPRIDE; TRIHEXYPHENIDYL; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZOPICLONE; ZOTEPINE;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN STEM; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEPRESSION; ECHOENCEPHALOGRAPHY; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; SENSITIVITY AND SPECIFICITY; TRANSCRANIAL SONOGRAPHY;

EID: 79955546477     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.100067     Document Type: Article

References (40)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83.
2. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66-72.
3. Nopoulos P, Magnotta VA, Mikos A, et al. Morphology of the cerebral cortex in preclinical Huntington's disease. Am J Psychiatry 2007;164:1428-34.
4. Sánchez-Pernaute R, Künig G, des Barrio Alba A, et al. Bradykinesia in early Huntington's disease. Neurology 2000;54:119-25.
5. Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry 2001;71:310-4.
6. Duff K, Paulsen JS, Beglinger LJ, et al.; Predict-HD Investigators of the Huntington Study Group. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD Study. Biol Psychiatry 2007;62:1341-6.
7. Becker G, Seufert J, Bogdahn U, et al. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995;45:182-4.
8. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008;7:1044-55.
9. Walter U, Niehaus L, Probst T, et al. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003;60:74-7.
10. Walter U, Krolikowski K, Tarnacke B, et al. Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease. Neurology 2005;64:1726-32.
11. Becker G, Becker T, Struck M, et al. Reduced echogenicity of brainstem raphe specific to unipolar depression: a transcranial colorcoded real-time sonography study. Biol Psychiatry 1995;38:180-4.
12. Becker G, Berg D, Lesch KP, et al. Basal limbic system alteration in major depression: a hypothesis supported by transcranial sonography and MRI findings. Int J Neuropsychopharmacol 2001;4:21-31.
13. Berg D, Supprian T, Hofmann E, et al. Depression in Parkinson's disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol 1999;246:1186-93.
14. Walter U, Prudente-Morrisey L, Herpertz SC, et al. Relationship of brainstem raphe echogenicity and clinical findings in depressive states. Psychiatry Res 2007;155:67-73.
15. Walter U, Hoeppner J, Prudente-Morrisey L, et al. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007;130:1799-987.
16. Postert T, Lack B, Kuhn W, et al. Basal ganglia alterations and brain atrophy in Huntington's disease depicted by transcranial real time sonography. J Neurol Neurosurg Psychiatry 1999;67:457-62.
17. Di Maio L, Squitieri F, Napolitano G, et al. Suicide risk in Huntington's disease. J Med Genet 1993;30:293-5.
18. Beck AT, Ward C, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
19. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
20. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136-42.
21. Penney JB, Vonsattel JP, MacDonald ME, et al. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-92.
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): The Association; 1994.
23. Walter U, Behnke S, Eyding J, et al. Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol 2007;33:15-25.
24. Landis JR, Koch GG. The measurement of observer agreement for categorial data. Biometrics 1977;33:159-74.
25. Paradiso S, Turner BM, Paulsen JS, et al. Neural bases of dysphoria in early Huntington's disease. Psychiatry Res 2008;162:73-87.
26. Zweig RM, Ross CA, Hedreen JC, et al. Locus coeruleus involvement in Huntington's disease. Arch Neurol 1992;49:152-6.
27. Licklederer C, Wolff G, Barth J. Mental health and quality of life after genetic testing for Huntington disease: a long-term effect study in Germany. Am J Med Genet 2008;146A:2078-85.
28. Julien CL, Thompson JC, Wild S, et al. Psychiatric disorders in preclinical Huntington's disease. J Neurol Neurosurg Psychiatry 2007;78:939-43.
29. Vlaar AM, Bouwmanns A, Mess WH, et al. Transcranial duplex in the differential diagnosis of parkinsonian syndromes. A systematic review. J Neurol 2009;256:530-8.
30. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59:999-1005.
31. Postert T, Eyding J, Berg D, et al. Transcranial sonography in spino cerebellar ataxia type 3. J Neural Transm Suppl 2004;68:123-33.
32. Grafton ST, Sumi SM, Stimac GK, et al. Comparison of postmortem magnetic resonance imaging and neuropathological findings in the cerebral white matter. Arch Neurol 1991;48:293-8.
33. Hayflick SJ, Harman M, Coryell J, et al. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006;27:1230-3.
34. Bartzokis G, Tischler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease. Cell Mol Biol 2000;46:821-33.
35. Hilditch-Maguire P, Trettel F, Passani LA, et al. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 2000;9:2789-97.
36. Naumann M, Becker G, Toyka KV, et al. Lenticular nucleus lesion in idiopathic dystonia detected by transcranial sonography. Neurology 1996;47:1284-90.
37. Becker G, Berg D, Rausch WD, et al. Increased tissue copper and manganese content in the lentiform nucleus in primary adult-onset dystonia. Ann Neurol 1999;46:260-3.
38. Seidel G, Kaps M, Gerriets T, et al. Evaluation of the ventricular system by transcranial duplex sonography in adults. J Neuroimaging 1995;5:105-8.
39. Walter U, Dressler D, Wolters A, et al. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 2004;63:504-9.
40. Peinemann A, Schuller S, Pohl C, et al. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci 2005;239:11-9.